No unexpected adverse events and biochemical side effects of olanzapine as adjunct treatment in adolescent girls with eating disorders

Journal of Child and Adolescent Psychopharmacology

Volumn 21, Issue 3, 2011, Pages 221-227

  Swenne, Ingemar ^a   Rosling, Agneta ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; OLANZAPINE; OXAZEPAM; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THYROXINE;

ADOLESCENT; ADOLESCENT HEALTH; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMENORRHEA; ANXIETY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; AUTOIMMUNE THYROIDITIS; BODY MASS; CLINICAL ARTICLE; COGNITIVE THERAPY; DEPRESSION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; EATING DISORDER; ENZYME ACTIVITY; EXERCISE; FEMALE; GALACTORRHEA; GLUCOSE BLOOD LEVEL; HUMAN; HYPERACTIVITY; INSULIN BLOOD LEVEL; LIPID BLOOD LEVEL; MALE; PROLACTIN BLOOD LEVEL; SEIZURE; SIDE EFFECT; STARVATION; THYROTROPIN BLOOD LEVEL; TONIC CLONIC SEIZURE; TREATMENT DURATION; TREATMENT INDICATION; TREATMENT RESPONSE; WEIGHT GAIN;

ADOLESCENT; AMENORRHEA; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BODY WEIGHT; CHILD; EATING DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE;

EID: 79958800891     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2009.0098     Document Type: Article

References (43)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. (DSM-IV). Washington, DC: American Psychiatric Association; 1994.
2. Atasoy N, Erdogan A, Yalug I, Ozturk U, Konuk N, Atik L, Ustundag Y: A review of liver function tests during treatment with antipsychotic drugs: A chart review. Progr Neurpsychopharmacol Biol Psychiatr 31:1255-1260, 2007. (Pubitemid 47081313)
3. Attia E, Schroeder L: Pharmacological treatment of anorexia nervosa: Where do we go from here? Int J Eat Disord 37:S60-S63, 2005. (Pubitemid 40605025)
4. Bissada H, Tasca GA, Barber AM, Bradwejn J: Olanzapine in the treatment of low body weight and obsessive thinking in women with anorexia nervosa: A randomized, double-blind, placebocontrolled trial. Am J Psychiatr 165:1281-1288, 2008.
5. Brambilla F, Garcia CS, Fassino S, Daga GA, Favaro A, Santonastoso P: Olanzapine therapy in anorexia nervosa: Psychobiological effects. Int Clin Psychopharmacol 22:197-204, 2007. (Pubitemid 46801942)
6. Centorrino F, Price BH, Tuttle M, Bahk W-M, Hennen J, Albert MJ, Baldessarini RJ: EEG abnormalities during treatment with typical and atypical antipsychotics. Am J Psychiat 159:109-115, 2002. (Pubitemid 41070735)
7. Correll CU: Assessing and maximizing the safety and tolerability of antipsychotics used in the treatment of children and adolescents. J Clin Psychiatr 69(suppl 4):26-36, 2008.
8. Crow SJ, Mitchell JE, Roerig JD, Steffen K: What potential role is there for medication treatment in anorexia nervosa? Int J Eat Disord 42:1-8, 2009.
9. Dickson RA, Glazer WM: Neuroleptic-induced hyperprolactinemia. Schizophrenia Res 35:S75-S86, 1999. (Pubitemid 29133028)
10. Domon SE, Webber JC: Hyperglycemia and hypertriglyceridemia secondary to olanzapine. J Child Adolesc Psychopharmacol 11:285-288, 2001. (Pubitemid 32937640)
11. Fairburn CG: Evidence-based treatment of anorexia nervosa. Int J Eat Disord 37:S26-S30, 2005. (Pubitemid 40605018)
12. Fraguas D, Merchán-Naranjo J, Laita P, Parellada M, Moreno D, Ruiz-Sancho A, Cifuentes A, Giráldez M, Arango C: Metabolic and hormonal side effects in children and adolescents treated with second-generation antipsychotics. J Clin Psychiatr 69:1166-1175, 2008. (Pubitemid 352031601)
13. Fukushima M, Nakai Y, Taniguchi A, Imura H, Nagata I, Tokuyama K: Insulin sensitivity, insulin secretion, and glucose effectiveness in anorexia nervosa: A minimal model analysis. Metabolism 42:1164-1168, 1993. (Pubitemid 23292693)
14. Gex-Fabry M, Balant-Gorgia AE, Balant LP: Therapeutic drug monitoring of olanzapine: The combined effect of age, gender, smoking, and comedication. Therapeut Drug Monitor 25:46-53, 2003. (Pubitemid 36139825)
15. Goran MI, Gower BA: Longitudinal study on pubertal insulin resistance. Diabetes 50:2444-2450, 2001. (Pubitemid 33642760)
16. Gowers SG: Management of eating disorders in children and adolescents. Arch Dis Child 93:331-334, 2008. (Pubitemid 352025835)
17. Gungor N, Saad R, Janosky J, Arslanian S: Validation of surrogate estimates of insulin sensitivity and insulin secretion in children and adolescents. J Pediatr 144:47-55, 2004. (Pubitemid 38091421)
18. Holtkamp K, Konrad K, Kaiser N, Ploenes Y, Heussen N, Grzella I, Herpertz- Dahlmann B. A retrospective study of SSRI treatment in adolescent anorexia nervosa: Insufficient evidence for efficacy. J Psychiatr Res 39:303-310, 2005. (Pubitemid 40255915)
19. Huang TTK, Johnson MS, Goran MI: Development of a prediction equation for insulin sensitivity from anthropometry and fasting insulin in prepubertal and early pubertal children. Diabetes Care 25:1203-1210, 2002. (Pubitemid 41071173)
20. Konstatinos N, Fountoulakis KN, Kantartzis S, Siamouli M, Panagiotidis P, Kaprinis S, Iacovides A, Kaprinis G. Peripheral thyroid function in depression. World J Biol Psychiatr 7:131-137, 2006.
21. Lindenmeyer J-P, Nathan A-M, Smith RC: Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatr 62(suppl 23):30-38, 2001. (Pubitemid 32952692)
22. Lindgren G, Strandell A, Cole T, Healy M, Tanner J: Swedish population standards for height, weight and body mass index attained at 6 to 16 years (girls) or 19 years (boys). Acta Paediatr 84:1019-1028, 1995.
23. McKnight RF, Park RJ: Atypical antipsychotics and anorexia nervosa: A Review. Eur Eat Disorders Rev 18:10-21, 2010.
24. Mehler-Wex C, Romanos M, Kirchheiner J, Schulze UME: Atypical antipsychotics in severe anorexia nervosa in children and adolescents- review and case reports. Eur Eating Disorders Rev 16:100-108, 2008. (Pubitemid 351566271)
25. Melkersson K, Dahl M-L: Adverse metabolic effects associated with atypical antipsychotics. Drugs 64:701-723, 2004.
26. Misra M, Miller KK, Almazan C, Ramaswamy K, Aggarwal A, Herzog DB, Neubauer G, Breu J, Klibansky A: Hormonal and body composition predictors of soluble leptin receptor, leptin, and free leptin index in adolescent girls with anorexia nervosa and controls and relation to insulin sensitivity. J Clin Endocrinol Metab 89:3486-3495, 2004. (Pubitemid 38951925)
27. Mondraty N, Birmingham CL, Touyz S, Sundakov V, Chapman L, Beumont P: Randomized controlled trial of olanzapine in the treatment of anorexia nervosa. Australasian Psychiatr 13:72-75, 2005. (Pubitemid 40514990)
28. Ohwada R, Hotta M, Oikawa S, Takano K: Etiology of hypercholesterolemia in patients with anorexia nervosa. Int J Eat Disord 39:598-601, 2006. (Pubitemid 44621815)
29. Saito E, Correll CU, Gallelli K, McMeniman M, Parikh UH, Malhotra AK, Kafantaris V: A prospective study of hyperprolactinemia in children and adolescents treated with atypical antipsychotic agents. J Child Adolesc Psychopharmacol 14: 350-358, 2004. (Pubitemid 39473121)
30. Schachter M, Shoham Z: Amenorrhea during the reproductive years- is it safe? Fertil Steril 62:1-16, 1994.
31. Schwartz B, Steinberger J, Jacobs DR, Hong C-P, Moran A, Sinaiko AR: Measurement of insulin sensitivity in children. Diabetes 31:783-788, 2008.
32. Staller J: The effect of long-term antipsychotic treatment on prolactin. J Child Adolesc Psychopharmacol 16:317-326, 2006. (Pubitemid 43902428)
33. Stigler KA, Potenza MN, McDougle CJ: Tolerability profile of atypical antipsychotics in children and adolescents. Paediatr Drugs 3:927-942, 2001. (Pubitemid 34074818)
34. Stübner S, Grohmann R, Engel R, Bandelow B, Ludwig W-D, Wagner G, Müller-Oerlinghausen B, Möller H-J, Hippius H, Rüther E: Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry 27(supp1):S70-S78, 2004. (Pubitemid 38658333)
35. Swenne I: The significance of routine laboratory analyses in the assessment of teenage girls with eating disorders and weight loss. Eating Weight Disord 9:269-278, 2004a.
36. Swenne I: Weight requirements for return of menstruations in teenage girls with eating disorders, weight loss and secondary amenorrhea. Acta Paediatr 93:1449-1455, 2004b. (Pubitemid 39457058)
37. Swenne I: Haematological changes and iron status in teenage girls with eating disorders and weight loss-the importance of menstrual status. Acta Paediatr 96:530-533, 2007. (Pubitemid 46466107)
38. Swenne I, Stridsberg M, Thurfjell B, Rosling A: Triiodothyronine is an indicator of nutritional status in adolescent girls with eating disorders. Horm Res 71:268-275, 2009.
39. Theisen FM, Haberhausen M, Schulz E, Fleischhaker C, Clement HW, Heinzel-Gutenbrunner M, Remschmidt H: Serum levels of olanzapine and its N-methyl and 2-hydroximethyl metabolites in child and adolescent psychiatric disorders: Effects of dose, diagnosis, age, sex, smoking and comedication. Ther Drug Monit 28:750-759, 2006. (Pubitemid 44967654)
40. Walsh BT, Kaplan AS, Attia E, Olmsted M, Parides M, Carter JC, Pike KM, Devlin MJ, Woodside B, Roberto CA, Rockert W. Fluoxetine after weight restoration in anorexia nervosa. A randomized controlled trial. JAMA 295:2605-2612, 2006. (Pubitemid 43882335)
41. Weinbrenner T, Züger M, Jacoby GE, Herpertz S, Liedtke R, Sudhop T, Gouni-Berthold I, Axelson M, Berthold HK: Lipoprotein metabolism in patients with anorexia nervosa: A case-control study investigating the mechansims leading to hypercholesterolemia. Br J Clin Nutr 91:959-969, 2004. (Pubitemid 38931460)
42. Yager J, Devlin MJ, Halmi KA, Herzog DB, Mitchell JE, Powers P, Zerbe KJ (American Psychiatric Association Steering Committee on Practice Guidlines, Work group on eating disorders): Practice Guideline for treatment of patients with eating disorders, 3rd edition. Available at: www.psych.org, 2006.
43. Yasuhara D, Naruo T, Nagai N, Tanaka M, Muranaga T, Nozoe S: Insulinogenic index at 15 min as a marker of nutritional rehabilitation in anorexia nervosa. Am J Clin Nutr 77:292-299, 2003. (Pubitemid 36133368)